Resistance of Brain Tumours to Small-Molecule-Targeted Therapies: Lessons from Various Cancer Types
- 29 November 2016
- book chapter
- other
- Published by Springer Science and Business Media LLC in Resistance to Targeted Anti-Cancer Therapeutics
Abstract
No abstract availableThis publication has 100 references indexed in Scilit:
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)Neuro-Oncology, 2010
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 2009
- Chapter 3 The TRAIL to Targeted Therapy of Breast CancerPublished by Elsevier BV ,2009
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesDrug Resistance Updates, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006
- A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerProceedings of the National Academy of Sciences of the United States of America, 2006
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004